Clinical, laboratory and MRI parameters at baseline and at week 6 of the placebo and etanercept groups
| Group | Baseline | Week 6 | p Value | |
|---|---|---|---|---|
| Clinical and laboratory parameters | ||||
| DAS28 | Placebo | 4.1 ± 0.7 | 3.9 ± 1.1 | <0.001 |
| Etanercept | 5.0 ± 1.0 | 3.3 ± 0.8 | ||
| HAQ score | Placebo | 0.57 ± 0.39 | 0.60 ± 0.51 | 0.02 |
| Etanercept | 0.92 ± 0.69 | 0.57 ± 0.52 | ||
| CRP (mg/dl) | Placebo | 0.80 ± 0.41 | 0.99 ± 0.78 | <0.001 |
| Etanercept | 2.20 ± 2.08 | 0.57 ±0.63 | ||
| ESR (mm/h) | Placebo | 19.1 ± 9.6 | 22.5 ± 15.1 | 0.003 |
| Etanercept | 28.4 ± 13.6 | 16.9 ± 14.7 | ||
| MRI parameters | ||||
| RAMRIS synovitis (0–21) | Placebo | 6.5 (5.2–9.0) | 6.0 (4.2–8.0) | 0.07 |
| Etanercept | 13.0 (7.0–14.0) | 9.0 (5.0–12.0) | ||
| RAMRIS bone marrow oedema (0–69) | Placebo | 5.0 (2.0–15.0) | 6.0 (0.5–20.7) | 0.36 |
| Etanercept | 15.0 (4.0–22.0) | 13.0 (4.0–20.0) | ||
| RAMRIS erosion (0–230) | Placebo | 13.0 (7.2–36.5) | 14.5 (7.0–37.7) | 0.26 |
| Etanercept | 27.0 (16.0–53.0) | 27.0 (12.0–53.0) | ||
| RAMRIS total (0–320) | Placebo | 24.5 (13.7–61.2) | 30.0 (10.5–60.5) | 0.11 |
| Etanercept | 59.0 (25.0–90.0) | 55.0 (21.0–80.0) | ||
| Tenosynovitis (0–26) | Placebo | 6.0 (5.0–7.7) | 6.0 (3.2–9.5) | 0.01 |
| Etanercept | 8.0 (4.0–12.0) | 6.0 (3.0–13.0) | ||
| MRI total inflammation (synovitis + tenosynovitis + bone marrow oedema) (0–116) | Placebo | 18.5.0 (13.2–32.7) | 15.0 (8.2–21.5) | 0.02 |
| Etanercept | 38.0 (19.0–47.0) | 29.0 (16.0–40.0) | ||
| MRI inflammation (synovitis + tenosynovitis) (0–47) | Placebo | 12.0 (11.0–15.0) | 11.5 (8.2–17.7) | 0.007 |
| Etanercept | 17.0 (12.0–26.0) | 17.0 (8.0–22.0) | ||
Values are medians (ranges) and mean ± SD.
CRP, C-reactive protein; DAS28, disease activity score 28-joint assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RAMRIS, Rheumatoid Arthritis Magnetic Resonance Imaging Score.